Hangzhou Sumgen Biotech Co., Ltd.
Clinical trials sponsored by Hangzhou Sumgen Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug targets Hard-to-Treat cancers by homing in on a specific protein Results expected Feb 2027 (estimated)
- Can a new infusion stop the Body's attack on a transplanted kidney? Results expected Mar 2027 (estimated)
- New antibody combo aims to stall multiple Myeloma's return Results expected Mar 2027 (estimated)
- Experimental injection aims to boost platelets in chronic blood disorder Results expected May 2027 (estimated)
-
Can a Triple-Drug combo shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis study tests whether an experimental drug called SG1827, when combined with an anti-PD-1/PD-L1 antibody and bevacizumab, is safe and shows early signs of fighting advanced solid tumors. The trial enrolls adults with unresectable or metastatic solid tumors who have already tri…
Phase 1/2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a new infusion stop the Body's attack on a transplanted kidney?
Disease control Not yet recruitingThis trial tests an experimental drug called SG301 in people who have antibody-mediated rejection after a kidney transplant. The goal is to see if the drug is safe and may help control the immune system's attack on the new kidney. Participants receive the drug by infusion weekly …
Phase 2 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC